A middle-market private equity investment firm, Amulet Capital Partners has acquired Alliance Clinical Network (ACN), a comprehensive clinical site platform.

Founded in 2014, ACN operates six clinical research sites across three US states –California, Nevada and Texas, and serves contract research organisations, patients as well as pharmaceutical sponsors.

ACN provides services in various clinical therapeutic areas including dermatology, gastroenterology, neurology, pain, vaccines and women’s health.

It has an expertise in enrolling diverse patient populations and focuses on Phase II and Phase III general medicine trials.

Leveraging its tech-enabled business model, ACN is into developing de novo sites.

ACN claims to have supported more than 75 clinical trials for over 40 sponsors varying from emerging biotechs to large pharma in 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the partnership with Amulet, ACN intends to grow its footprint via de novo development and strategic acquisitions.

 It also wants to enhance its capabilities in other therapeutic areas and build on its presence in vaccines.

Anthony Abey will continue to lead as ACN’s founder and CEO in addition to retaining a significant ownership stake in the business.

Financial terms of the transaction have not been disclosed.

Amulet partner Nick Amigone said: “For prominent sponsors, ACN’s scalable, technology-driven approach has established the platform as a partner of choice with exceptional on-site expertise and a patient-centric focus that consistently drives successful outcomes.

“We see a tremendous opportunity to grow and expand the platform and the exceptional team Anthony has built to position the business for long-term success.

“We look forward to working together to continue delivering high-quality results that exceed the expectations of our sponsor and CRO clients, while providing opportunities for a diverse set of patients to participate in clinical research.”